期刊文献+

波生坦治疗先天性心脏病合并肺动脉高压的研究进展 被引量:7

下载PDF
导出
摘要 肺动脉高压(pulmonary arterial hypertension,PAH)是一种少见的预后不良的疾病,以肺动脉压力和阻力增高为特征[1]。先天性心脏病(congenital heart disease,CHD,先心病)体-肺分流型是由于缺损部位大量左向右分流导致肺循环容量明显增加,肺血管处于高流量高压力状态,肺动脉压力阻力升高,引起PAH。
出处 《心肺血管病杂志》 CAS 2012年第3期351-352,共2页 Journal of Cardiovascular and Pulmonary Diseases
  • 相关文献

参考文献10

  • 1李强强,顾虹,罗毅.先天性心脏病合并肺动脉高压的药物治疗进展[J].心肺血管病杂志,2009,28(3):212-214. 被引量:28
  • 2张雅娟,胡盛寿,李守军,郑哲,李永青,王旭,王阳.波生坦治疗先天性心脏病术后肺动脉高压的前瞻性随机对照研究[J].中华胸心血管外科杂志,2010,26(6):380-384. 被引量:7
  • 3刘海涛,池木根.内皮素受体拮抗剂波生坦在治疗心脑血管疾病中的临床应用[J].国外医学(药学分册),2004,31(3):157-160. 被引量:1
  • 4D'Alto M,Romeo E,Argiento P,et al.Therapy for pulmonaryarterial hypertension due to congenital heart disease and Down'ssyndrome.Int J Cardiol,2011.
  • 5Van Loon RL,Hoendermis ES,Duffels MG,et al.Long-termeffect of bosentan in adults versus children with pulmonary arteri-al hypertension associated with systemic.to-pulmonary shunt:does the beneficial effect persistAm Heart J,2007,54:776-782.
  • 6徐卓明,朱丽敏,蔡小满,季罡,刘锦纷,苏肇伉.波生坦治疗儿童先天性心脏病相关肺动脉高压的疗效观察[J].中华医学杂志,2009,89(30):2106-2109. 被引量:15
  • 7Galie N,Beghetti M,Gatzoulis MA,et al.Bosentan randomizedtrial of endothelin antagonist therapy.Bosentan therapy in patientswith Eisenmenger syndrome:a multicenter,double-blind,ran-domized,placebo-controlled study.Circulation,2006,114:48-54.
  • 8Apostolopoulou SC,Manginas A,Cokkinos DV,et al.Long-termoral bosentan treatment in patients with pulmonary arterial hyper-tension related to congenital heart disease:a 2-year study.Heart,2007,3:350-354.
  • 9Gatzoulis MA,Beghetti M,Galie N,et al.Longer-term bosentantherapy improves functional capacity in Eisenmenger syndrome:Results of the BREATHE-5 open-label extension study.Int J Car-diol,2007,19:11-21.
  • 10Gatzoulis MA,Beghetti M,Galie N,et al.Longer-term bosentantherapy improves functional capacity in Eisenmenger syndrome:results of the BREATHE-5 open-label extension study.Int J Car-diol,2007,127:27-32.

二级参考文献52

  • 1Singh TP,Rohit M,Grover A,菅鑫妍.口服西地那非疗法治疗严重肺动脉高压的效果研究[J].中国处方药,2006(8):29-29. 被引量:49
  • 2Ma M, Gauvreau K, Allan CK, et al. Causes of death after congenital heart surgery. Ann Thorac Surg, 2007, 83 : 1438-1445.
  • 3Hawort SG. The management of pulmonary hypertension in children. Arch Dis Child, 2008, 93:620-625.
  • 4Hsu HH, Chen JS, Chen RJ, et al. Long-term outcome and effects of oral bosentan therapy in Taiwan Residents patients with advanced idiopathic pulmonary arterial hypertension. Respir Med, 2007, 101 : 1556-1562.
  • 5Lammers AE, Hislop AA, Flynn Y, et al. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child, 2008, 93:464-468.
  • 6Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant, 2007, 26 : 181-187.
  • 7Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 2006, 114 : 48-54.
  • 8Barst R, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther, 2003, 73:372-382.
  • 9Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol, 2005, 46:697-704.
  • 10Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart, 2009, 95:312-317.

共引文献45

同被引文献76

  • 1成革胜,张玉顺,杜亚娟,何璐,王星烨.靶向药物联合介入治疗先天性心脏病合并重度肺动脉高压的安全性及疗效[J].心血管外科杂志(电子版),2014,3(1):19-22. 被引量:9
  • 2何红文.室间隔缺损并肺动脉高压的围手术期护理[J].护士进修杂志,2004,19(7):636-637. 被引量:9
  • 3Barst RJ,Langleben D,Badesch D,菅鑫妍.使用选择性内皮素A受体拮抗剂sitaxsentan治疗肺动脉高压[J].中国处方药,2006,5(8):29-29. 被引量:38
  • 4李玉芬.先天性心脏病术后肺动脉高压危象的预防及护理[J].护士进修杂志,2007,22(19):1787-1788. 被引量:16
  • 5Alan D,Kaye,Tyler B. Left-to-right cardiac shunt:perioperative anesthetic considerations[J].Middle East Journal of Anesthesiology,2012,(06):793-806.
  • 6Rose ML,Strange G,King I. Congenital heart disease-associated pulmonary arterial hypertension:preliminary results from a novel registry[J].Internal Medicine Journal,2012,(08):874-879.
  • 7Komai H, Adatia IT, Elliott M J, et al. Increased plasma Ievels of endothelin after cardiopulmonary bypass in patients with pulmonary hyperWnsion nd congenital he disease[J]. J Thorae Cardiovasc Surg, 1993, 106: 473- 478.
  • 8Kaye AD, Stout TB, Padnos IW, et al. Left-to-right car-diac shunt: perioperative anesthetic considerations [ J ]. Middle East J Anaesthesiol, 2012, 21 (6) : 793-806.
  • 9Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension [ J ]. Pharmacol Res, 2011, 63(6): 504-511.
  • 10Abman SH, Kinsella JP, Rosenzweig EB, et al. Implica- tions of the U. S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension[ J]. Am J Respir Crit Care Med, 2013, 187(6) : 572-575.

引证文献7

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部